Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA4 | P22748 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23004872 | 1.00 | CA1 (0.60) | CA1CA2CA4SIGMAR1SLC18A3 | |
| SCHEMBL5037292 | 1.00 | CA1 (0.60) | CA1CA2CA4SIGMAR1SLC18A3 | |
| SCHEMBL9154803 | 0.86 | CA1 (0.56) | CA1CA2CA4SIGMAR1SLC18A3 | |
| SCHEMBL13495040 | 0.81 | CA1 (0.40) | CA1CA2CA4 | |
| SCHEMBL201965 | 0.81 | SIGMAR1 (0.40) | CA1CA2CA4SIGMAR1NOS3 | |
| SCHEMBL862022 | 0.79 | — | — | |
| SCHEMBL6443728 | 0.79 | — | — | |
| SCHEMBL1413431 | 0.79 | — | — | |
| SCHEMBL1413545 | 0.79 | — | — | |
| SCHEMBL3975908 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705275-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2026-03-11 | — | — | EP | disclosed |
| US-20240417370-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-12-19 | — | — | US | disclosed |
| WO-2024233387-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-11-14 | — | — | WO | disclosed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1680666-A4 | DETECTING HUMAN ANTI-THERAPEUTIC ANTIBODIES | MONOGRAM BIOSCIENCES INC (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1680666-A2 | DETECTING HUMAN ANTI-THERAPEUTIC ANTIBODIES | Monogram Biosciences, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005045058-A2 | DETECTING HUMAN ANTI-THERAPEUTIC ANTIBODIES | MONOGRAM BIOSCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-6596718-B1 | A compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor. | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417370-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | LIPA, PHOSPHO1, LIPC | CA1 2767/4885CA2 3487/4885CA4 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.